How is the industry reacting to this shift in leveraging remote strategies?
How do we balance key factors such as patient centricity, data, regulation, compliance and cost, and should flexibility be the greatest priority?
What impact is this having on the regulators and how they operate?
Will remote trials affect data endpoints and to what extent?
What impact do virtual, decentralised and hybrid trials have on patients and how can we reduce potential burdens?
How is this influencing patient engagement strategies?
Unsupported Browser Detected
The browser you are using is not supported that will prevent you from accessing certain features of the website. We want you to have the best possible experience. For this you'll need to use a supported browser and upgrade to the latest version.